FOGHORN THERAPEUTICS INC (FHTX)
Health Care · biotechnology · NASDAQ
Foghorn Therapeutics is a clinical-stage biotech developing precision medicines by targeting the chromatin regulatory system to correct abnormal gene expression in cancer and other diseases.
What FOGHORN THERAPEUTICS INC does
Foghorn Therapeutics is a clinical-stage biotechnology company focused on treating serious diseases by modulating the chromatin regulatory system. The company uses its proprietary Gene Traffic Control® platform to identify, validate, and target genetic dependencies involved in oncology, immunology, and inflammation. Its product pipeline includes small molecule approaches such as targeted protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors.
Recent developments
The company is advancing the Phase 1 dose-escalation trial for FHD-909 (in collaboration with Eli Lilly) for SMARCA4-mutant NSCLC and plans to file INDs for its selective EP300 degrader and a novel oral small molecule in immunology and inflammation in 2027. The company successfully completed a $50 million common stock and warrant offering in January 2026.
From FOGHORN THERAPEUTICS INC's filing of 2026-08-06.
Themes: precision medicine, epigenetics, targeted protein degradation, oncology pipeline, immunology and inflammation, synthetic lethality
Fundamentals
- Price$1.99 as of 2026-10-08 close
- Market cap$118M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-55.8% 2025-10-08 close $4.50 → 2026-10-08 close $1.99
- P/En/a negative earnings
- Net margin-240.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+52.0% as of 2026-09-03
- Revenue CAGR (3y)+17.1% SEC XBRL
- Beta1.59 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How FHTX compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FOGHORN THERAPEUTICS INC looks technically
FOGHORN THERAPEUTICS INC (FHTX) is trading 60.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 3 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 16, in oversold territory (below 30). It made a new 20-day low about 3 trading days ago. It is 73.9% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 60.3% below its 200-day average, the long-term trend line — a long-term downtrend | -60.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.87 | $4.87 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.01 | $5.01 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 3 trading days ago — a "death cross", a bearish long-term signal | 3 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 53, with sellers in control | 52.9 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 16, in oversold territory (below 30) | 15.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($1.79 to $4.32) — its "stochastic" reading is 8 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 7.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.61 | $7.61 |
|---|---|---|
| From the 52-week high | it is 73.9% below its 52-week high (its highest price of the past year) | -73.8% |
| Above the 52-week low | it is 11.2% above its 52-week low (its lowest price of the past year) | +11.2% |
| Below the 52-week high | it is 73.9% below its highest point of the past year | 73.8% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $24.16 (set on 2022-01-03) | $24.16 |
| Given back of the 52-week move | over the past year its closes ranged ($1.97 to $7.07), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.12 to $5.29. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.4% |
| From the all-time high | it is 91.8% below its all-time high | -91.8% |
| Nearest price level | it is trading 79.2% below a resistance level at $3.56 — a price it turned at three times since 2025-05-06, most recently on 2026-06-03. Since 2024-10-08 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +79.2% |
| All-time low | its lowest closing price on record is $1.79 (set on 2026-10-01) | $1.79 |
| Above the all-time low | it is 11.2% above its all-time low | +11.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3683 between its high and its low — about 18.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3683 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.65 and $5.19 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.65 – $3.42 – $5.19 |
| Typical daily range (% of price) | its price moves about 18.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 18.5% |
| Stretch from the 200-day average | it is trading 8.2 daily ranges below its 200-day average price (60.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.23× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 13.6% since the prior reading | -13.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.9% |
|---|---|---|
| Open gap | it gapped 41.7% below the previous close 5 sessions ago and has not traded back through the level it left behind at 3.57 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -41.7% |
| Gap filled | a 2.5% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 59.8 percentage points (the stock lost 58.8% while the market gained 1.0%) | -59.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 71.6 percentage points (the stock lost 67.7% while the market gained 3.8%) | -71.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 76.7 percentage points (the stock lost 59.2% while the market gained 17.5%) | -76.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 70.8 percentage points (the stock lost 55.8% while the market gained 15.0%) | -70.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 66% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 23.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -65.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 54% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.36 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -54.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 47% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.77 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -47.2% |
Price levels it has turned at before
FHTX last closed at $1.99 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.56 | Resistance | 79.2% above the last close | turned there three times · 2025-05-06 to 2026-06-03 |
| $3.85 | Resistance | 93.7% above the last close | turned there twice · 2025-01-29 to 2025-04-09 |
| $4.24 | Resistance | 113.1% above the last close | turned there twice · 2025-12-03 to 2025-12-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$6.00 range $2.00 – $14.00; median $5.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FHTX
- Consensus EPS estimate-$0.2514 next reporting period, as of 2026-10-09
- Estimate change, 30 days-$0.02143 from -$0.23, on 2026-09-04, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on strategic collaborations, specifically with Eli Lilly, for the development and funding of key programs.","Clinical-stage company with no products approved for commercial sale and a history of significant operating losses.","Uncertainty of the clinical trial success for novel therapeutic approaches targeting the complex chromatin regulatory system."]
What changed in the latest 10-Q
AI-assisted comparison of FHTX's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) adds '("I&I")' after 'immunology and inflammation' in the first Overview paragraph when introducing Foghorn.
- Newer filing (2026-08-06) adds 'For the six months ended June 30, 2026 and the year ended December 31, 2025, we reported net losses of $27.1 million and $74.3 million, respectively. As o' near the end of the comparison text (text may be truncated).
- Removed:
- Older filing (2026-05-07) contains a paragraph stating: 'In December 2024, we announced our decision to discontinue the independent development of FHD-286 in combination with decitabine in patients with relapsed and/or refractory acute myeloid leukemia.' This paragraph is not present in the newer filing (2026-08-06).
- Reworded:
- Newer filing (2026-08-06) changes 'At present, we are working on more than seven programs' to 'Our current pipeline consists of more than seven programs' in the Overview section.
- Newer filing (2026-08-06) changes 'the most challenging targets in oncology including SMARCA2 (BRM), CBP, EP300, and ARID1B' to 'the most challenging targets in oncology and I&I, including SMARCA2 (BRM), CBP, EP300, and ARID1B' in the Overview section.
- Newer filing (2026-08-06) changes 'help more than 500,000 cancer patients' to 'help more than 500,000 patients' in the Overview section.
- Notes:
- The newer filing text ends abruptly with 'As o' and may be truncated, so changes after that point could not be assessed.
- Both sections are from the Foghorn Therapeutics Inc. (FHTX) 10-Q filings and describe certain historical events but comparison is limited to the provided texts.
Risk Factors
- Reworded:
- In the newer filing (filed 2026-08-06), Item 5. Other Information refers to 'During the three months ended June 30, 2026'; in the older filing (filed 2026-05-07), the same sentence refers to 'During the three months ended March 31, 2026'.
- Notes:
- The Risk Factors section itself is identical in both filings: both state there have been no material changes to the risk factors disclosed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for FHTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding FHTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,725,839
- Reported value $47,462,093
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about FHTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
FHTX had 1,992,972 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
FHTX had 3.36% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.2 days to cover at the same settlement.
- Reported short interest (shares) 1,992,972
- Short interest (% of shares outstanding) 3.36%
- Prior settlement (shares) 1,969,434
- Reported change 1.2%
- Days to cover (reported) 5.2
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kura Oncology (KURA)
- Nurix Therapeutics (NRIX)
- Kymera Therapeutics (KYMR)
- Arvinas (ARVN)
- C4 Therapeutics (CCCC)
- Relay Therapeutics (RLAY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FHTX vs…
Frequently asked questions
What does FOGHORN THERAPEUTICS INC (FHTX) do?
Foghorn Therapeutics is a clinical-stage biotechnology company focused on treating serious diseases by modulating the chromatin regulatory system. The company uses its proprietary Gene Traffic Control® platform to identify, validate, and target genetic dependencies involved in oncology, immunology, and inflammation. Its product pipeline includes small molecule approaches such as targeted protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors.
What sector is FOGHORN THERAPEUTICS INC (FHTX) in?
FOGHORN THERAPEUTICS INC (FHTX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are FOGHORN THERAPEUTICS INC's (FHTX) competitors?
Notable peers of FOGHORN THERAPEUTICS INC (FHTX) include Kura Oncology, Nurix Therapeutics, Kymera Therapeutics, Arvinas and C4 Therapeutics. This peer set is informational only — not financial advice.
Is FOGHORN THERAPEUTICS INC (FHTX) overbought or oversold right now?
FOGHORN THERAPEUTICS INC (FHTX) is currently in oversold territory (its 14-day RSI is 16, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FHTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.